Equities research analysts expect Endocyte, Inc. (NASDAQ:ECYT) to report earnings per share of ($0.16) for the current quarter, Zacks reports. Zero analysts have made estimates for Endocyte’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Endocyte reported earnings of ($0.26) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The business is scheduled to report its next quarterly earnings results on Friday, March 9th.

According to Zacks, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts anticipate that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Endocyte.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The business had revenue of $0.03 million for the quarter. During the same period last year, the company posted ($0.21) EPS. Endocyte’s revenue for the quarter was up .0% compared to the same quarter last year.

Several equities research analysts have recently commented on the stock. ValuEngine cut shares of Endocyte from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. Finally, Cowen restated a “hold” rating on shares of Endocyte in a report on Monday, October 2nd.

Shares of Endocyte (NASDAQ ECYT) traded down $0.02 during trading hours on Friday, hitting $4.34. 178,112 shares of the stock traded hands, compared to its average volume of 427,073. Endocyte has a 12 month low of $1.17 and a 12 month high of $6.55. The firm has a market cap of $208.76, a PE ratio of -3.19 and a beta of 2.20.

In related news, insider Philip S. Low sold 50,511 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $4.41, for a total transaction of $222,753.51. Following the completion of the transaction, the insider now owns 354,050 shares in the company, valued at $1,561,360.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Philip S. Low acquired 5,600 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average price of $4.84 per share, with a total value of $27,104.00. Following the acquisition, the insider now owns 283,005 shares of the company’s stock, valued at approximately $1,369,744.20. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 124,253 shares of company stock valued at $562,591. Corporate insiders own 14.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after buying an additional 393,975 shares during the period. FMR LLC boosted its holdings in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after buying an additional 31,168 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 25,003 shares during the period. Hedge funds and other institutional investors own 17.58% of the company’s stock.

WARNING: “Zacks: Brokerages Expect Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.16 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/06/zacks-brokerages-expect-endocyte-inc-ecyt-will-announce-earnings-of-0-16-per-share.html.

Endocyte Company Profile

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.